Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Losartan + metoprolol is a combination of two antihypertensive agents used together to manage high blood pressure and certain heart conditions. Losartan is an angiotensin II receptor blocker (ARB) that works by blocking the action of angiotensin II, leading to vasodilation and reduced blood pressure. Metoprolol is a beta-adrenergic blocker (beta-blocker) that reduces heart rate, cardiac output, and the workload on the heart by blocking beta-1 adrenergic receptors in the heart. This combination may be prescribed for hypertension, cardiomyopathy, congestive heart failure, or other cardiovascular indications where dual blockade of these pathways provides additive benefit[1][6][7]. Both drugs are available as generics and are commonly co-prescribed but not typically formulated as a single fixed-dose combination tablet.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on losartan + metoprolol.